Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Journey through Pages: A Survey of \Plunging into Scholarly Universes\ - 2Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- 3The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- 4Sustaining Public activity and Connections: Key Methodologies
- 5Court clears Beersheba assault suspect of link to Haymanut Kasau disappearance, extends detention
- Munich Security Conference chief defends inviting AfD lawmakers
- Select Your Cherished Fish
- James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- First Greenland, now Iceland? Annexation joke by Trump ally gets frosty response in the Arctic nation.
- 6 Arranging Administrations to Change Your Open air Space
- Where America’s CO2 emissions come from – what you need to know, in charts
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
- Make your choice for the music application with the most amicable connection point!
- As world leaders enter climate talks, people in poverty have the most at stake
